Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Novartis
Actuate Therapeutics Inc.
Novartis
Amgen
Hoffmann-La Roche
Daiichi Sankyo
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Boehringer Ingelheim
Telix Pharmaceuticals (Innovations) Pty Limited
Daiichi Sankyo
Sumitomo Pharma America, Inc.
GT Medical Technologies, Inc.
InSightec
In8bio Inc.
Servier
Oblato, Inc.
Mingge LLC
Mingge LLC